Clinical Stage Immuno-Oncology player, Imugene Limited (ASX:IMU) has revealed the outcome of the HER-Vaxx Phase 2 IDMC (Independent Data Monitoring Committee) meeting. The Company notified that IDMC has confirmed HER-Vaxx safety and recommended continuation of study without modification.
In addition, Imugene informed that the patients receiving HER-Vaxx cancer immunotherapy are responding actively. To recall, the Company is continuing with HER-Vaxx Phase 2 clinical trial involving 68 HER-2+ metastatic gastric cancer patients.
IMU is currently trading at $0.026 as at 11:46 AM AEST on 4th May 2020.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.